Market Cap | 123.03M | P/E | - | EPS this Y | 67.60% | Ern Qtrly Grth | - |
Income | -42.12M | Forward P/E | -8.26 | EPS next Y | -4.90% | 50D Avg Chg | -1.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 39.00% |
Dividend | N/A | Price/Book | 0.73 | EPS next 5Y | - | 52W High Chg | -45.00% |
Recommedations | 1.50 | Quick Ratio | 40.57 | Shares Outstanding | 25.65M | 52W Low Chg | 216.00% |
Insider Own | 14.27% | ROA | -25.87% | Shares Float | 16M | Beta | - |
Inst Own | 55.75% | ROE | -39.66% | Shares Shorted/Prior | 1.79M/663.46K | Price | 2.81 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 582,543 | Target Price | 58.33 |
Oper. Margin | - | Earnings Date | May 13 | Volume | 112,276 | Change | -3.44% |
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Truist Securities | Buy | Mar 25, 24 |
Jefferies | Buy | Mar 20, 24 |
HC Wainwright & Co. | Buy | Mar 20, 24 |
Jefferies | Buy | Dec 15, 23 |
Truist Securities | Buy | Nov 17, 23 |
Guggenheim | Buy | Oct 31, 23 |
Piper Sandler | Overweight | Oct 25, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Kulkarni Sandeep Chidambar | CEO CEO | Nov 17 | Buy | 16.99 | 4,000 | 67,960 | 729,735 | 11/20/23 |
Thiara Parvinder | Director Director | Nov 17 | Buy | 17.31 | 1,000 | 17,310 | 83,782 | 11/20/23 |
Castelein Caley | Director Director | Oct 25 | Buy | 13.31 | 20,000 | 266,200 | 516,519 | 10/27/23 |
Kulkarni Sandeep Chidambar | CEO CEO | Oct 24 | Buy | 11.47 | 9,650 | 110,686 | 725,735 | 10/26/23 |
KANTOFF AARON | Director Director | Oct 24 | Buy | 11.86 | 7,500 | 88,950 | 45,391 | 10/26/23 |
Thiara Parvinder | Director Director | Oct 24 | Buy | 11.39 | 7,000 | 79,730 | 82,782 | 10/26/23 |
Ildstad Suzanne | Director Director | Jun 12 | Sell | 2.55 | 44,020 | 112,251 | 3,771,392 | 06/14/23 |
Ildstad Suzanne | Director Director | Jun 07 | Sell | 2.44 | 141,062 | 344,191 | 3,815,412 | 06/09/23 |
Ildstad Suzanne | Director Director | Jun 05 | Sell | 2.52 | 33,390 | 84,143 | 2,756,474 | 06/07/23 |
Ildstad Suzanne | Director Director | Apr 21 | Sell | 2.3481 | 15,004 | 35,231 | 2,821,395 | 04/25/23 |
Ildstad Suzanne | Director Director | Mar 01 | Sell | 2.05 | 29 | 59 | 3,071,366 | 04/07/23 |
Ildstad Suzanne | Director Director | Feb 21 | Sell | 2.0529 | 3,500 | 7,185 | 3,071,395 | 04/07/23 |
Ildstad Suzanne | Director Director | Feb 16 | Sell | 2.05 | 6,551 | 13,430 | 3,074,895 | 04/07/23 |
Ildstad Suzanne | Chief Scientific Off.. Chief Scientific Officer | Aug 22 | Sell | 2.80 | 525,000 | 1,470,000 | 3,081,446 | 08/23/22 |
Requadt Scott | Chief Executive Offi.. Chief Executive Officer | Jul 29 | Buy | 4.25 | 39,382 | 167,374 | 508,680 | 08/02/22 |
Requadt Scott | Chief Executive Offi.. Chief Executive Officer | Jul 26 | Buy | 4.25 | 8,618 | 36,626 | 469,298 | 07/28/22 |
Requadt Scott | Chief Executive Offi.. Chief Executive Officer | Jul 22 | Buy | 3.7497 | 9,444 | 35,412 | 460,680 | 07/26/22 |
Nader Francois | Director Director | Jul 19 | Buy | 3.62 | 138,500 | 501,370 | 138,500 | 07/25/22 |